Emerging Trends in Global PEGylated Proteins Market Forecasted to Reach $2.1 Billion by 2028: Analysis of Key Players and Therapeutic Applications
PEGylation is an important process in the pharmaceutical industry that involves the covalent attachment of polyethylene glycol (PEG) molecules to therapeutic proteins, peptides, or liposomes. This process can help to improve the pharmacokinetics and pharmacodynamics of drugs, increase their stability, reduce their immunogenicity, and prolong their circulation time in the body.
According to a new market research report by ReportLinker, the global PEGylated proteins market is expected to grow at a CAGR of 6.7% from 2021 to 2028 and reach $2.1 billion by the end of the forecast period. What are some of the key trends driving this growth?
Increasing demand for biologics
Biologics are a class of drugs that are made from living cells, and they include PEGylated proteins, monoclonal antibodies, fusion proteins, and vaccines. Biologics have revolutionized the treatment of cancer, autoimmune diseases, and rare genetic disorders, and they are becoming more popular due to their high specificity, low toxicity, and ability to target multiple pathways.
As the population ages and the prevalence of chronic diseases increases, the demand for biologics is expected to grow. This is especially true in emerging markets such as India, China, Brazil, and Mexico, where there is a growing middle class and an increasing burden of disease.
Rising investments in R&D
The development of PEGylated proteins requires a significant investment of time, money, and expertise. It can take several years and millions of dollars to bring a drug from the laboratory to the market, and many compounds fail in clinical trials due to safety or efficacy concerns.
However, the potential rewards of successful drug development are substantial, and many companies are investing heavily in R&D to discover new indications, optimize existing products, and identify new targets. For example, Roche and Genentech are investing $1 billion in a new research center to accelerate the discovery of new biologics and small molecules.
Expanding applications in oncology and hematology
Oncology and hematology are two of the most promising areas for PEGylated proteins, as they have the potential to improve the safety and efficacy of chemotherapy, radiation therapy, and immunotherapy. For example, PEGfilgrastim (Neulasta) is a PEGylated version of the granulocyte-colony stimulating factor (G-CSF) that can reduce the risk of infection and fever in patients undergoing chemotherapy.
In addition, PEG-asparaginase (Oncaspar) is a PEGylated version of the enzyme asparaginase that can degrade the amino acid asparagine and deprive cancer cells of a vital nutrient. PEGylated interferon alpha (Pegasys) is another example of a PEGylated protein that is used to treat certain types of leukemia, melanoma, and Kaposi’s sarcoma.
Key players in the PEGylated proteins market
The global PEGylated proteins market is highly competitive and fragmented, with many small and large companies vying for market share. Some of the key players in the market include Amgen, Biogen, Bristol-Myers Squibb, Roche, Novartis, Pfizer, Sanofi, Merck, AbbVie, Alexion, and Jazz Pharmaceuticals.
These companies have different strengths and weaknesses, and they use different strategies to compete in the market. Some companies focus on developing innovative drugs for niche indications, while others focus on biosimilars or generics.
Summary
In conclusion, the global PEGylated proteins market is expected to grow at a CAGR of 6.7% from 2021 to 2028 and reach $2.1 billion by the end of the forecast period. This growth is driven by increasing demand for biologics, rising investments in R&D, and expanding applications in oncology and hematology. The market is highly competitive and fragmented, with many small and large players vying for market share. #BUSINESS